Guatemala

Community plant knowledge and evidence limits

Evidence at a glance

Scope: Botanical traditions and human research relevant to Guatemala. Evidence types: Ethnobotanical reports, observational studies, clinical trials or safety assessments where cited. Cancer control: No demonstrated cure from the traditional-use records summarized here. Limitation: Selective source review, not a systematic review.

Community-led pharmacopoeias

Collaborative ethnobotanical field research; no clinical efficacy testing. A 2016 Journal of Ethnopharmacology study worked with councils of elders among Kaqchikel highland and Q’eqchi’ lowland communities. Over 20 months it cataloged a combined 530 species. The authors explicitly describe culturally specific and changing knowledge. This is neither 530 proven medicines nor a single ancient recipe collection.

Q’eqchi’ women’s health practices

Ethnobotany plus laboratory receptor assays. A 2007 research paper identified 48 plants reported for pregnancy, childbirth, menstruation and menopause; 20 species underwent relevant laboratory testing. Receptor-binding effects cannot establish safe or effective use in pregnancy, relieve menopausal symptoms in patients, or support cancer hormonal therapies.

Modern community catalogs

Documented knowledge and stewardship, not randomized trials. PAHO’s December 2025 account describes a medicinal-plant catalog developed with Maya Ch’orti’ ancestral authorities, community practitioners and traditional birth attendants. Related Q’eqchi’ and Poqomchi’ work emphasizes cultural context and local-language identity. Public documentation does not grant outsiders permission to commercialize community knowledge.

Mental health and cancer claims

Literature synthesis with substantial preclinical gaps. A 2021 ethnopharmacology review identified 155 plants reported for mental or neurological conditions among Mesoamerican Maya groups, of which 49 native species had in-vitro or animal pharmacology reported. This is a map of research needs, not proof of treatment for depression, insomnia, epilepsy or cognitive decline. Nor is laboratory antitumor activity proof of tumor response, recurrence reduction or survival.

Clinical interpretation and safety

Documented traditional use does not establish treatment efficacy. Extracts, infusions, foods, and isolated compounds are different interventions. Laboratory cytotoxicity is not clinical tumor control. Review supplements and interactions with the treating team; do not substitute unverified products for established cancer care.

Sources: Primary references linked in the evidence sections above. Last chapter edit: October 18, 2026. Evidence scope: selective, not exhaustive. Evidence Explorer · Methods.